AI-ACCELERATED DRUG DISCOVERY
Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of WW domain-containing oxidoreductase including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into WW domain-containing oxidoreductase therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of WW domain-containing oxidoreductase, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on WW domain-containing oxidoreductase. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of WW domain-containing oxidoreductase. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for WW domain-containing oxidoreductase includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
WW domain-containing oxidoreductase
partner:
Reaxense
upacc:
Q9NZC7
UPID:
WWOX_HUMAN
Alternative names:
Fragile site FRA16D oxidoreductase; Short chain dehydrogenase/reductase family 41C member 1
Alternative UPACC:
Q9NZC7; A8K323; Q5MYT5; Q96KM3; Q96RF2; Q9BTT8; Q9NPC9; Q9NRF4; Q9NRF5; Q9NRF6; Q9NRK1; Q9NZC5
Background:
The WW domain-containing oxidoreductase, also known as Fragile site FRA16D oxidoreductase and Short chain dehydrogenase/reductase family 41C member 1, is a putative oxidoreductase. It acts as a tumor suppressor, playing a pivotal role in apoptosis and is essential for normal bone development. This protein is involved in controlling genotoxic stress-induced cell death, functions in TGFB1 signaling, and TGFB1-mediated cell death, and inhibits Wnt signaling by sequestering DVL2 in the cytoplasm.
Therapeutic significance:
WW domain-containing oxidoreductase is linked to several diseases, including Esophageal cancer, Spinocerebellar ataxia, autosomal recessive, 12, and Developmental and epileptic encephalopathy 28. Its role in apoptosis and tumor suppression makes it a target for therapeutic strategies aimed at these conditions.
